Search

everythinglearnresearchcommunity

for

Search:↓

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

Sirolimus and propranolol may reduce abnormal cell growth and improve lymphatic malformations in children.

All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.

A man with X-ALD improved after treatment, highlighting the need to consider X-ALD in similar patients and test their relatives.

H-1 antihistamines may help with various skin conditions, but more research is needed to confirm their effectiveness.

A nutrition program significantly improved a woman's lupus symptoms.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

SIG-1451 could be a promising new treatment for atopic dermatitis.

Timely treatment of eosinophilic asthma in rheumatic disease patients can prevent organ damage.

Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.

The emulgel with 11.5% oil and 1.75% gelling agent effectively delivers fluconazole topically with improved spreadability and stability.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.

Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.

The 308-nm excimer laser is a promising treatment for vitiligo with varying success and mild side effects.

Finasteride helps improve treatment for benign prostatic hyperplasia.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Tofacitinib improved hair and nail conditions in a teen with alopecia areata.

Imatinib can cause hair loss due to lichen planopilaris.

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

Acitretin effectively treats severe hypertrophic lichen planus.

Blocking IL-8 can reduce skin rashes from cancer treatment.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Azithromycin can rarely cause a severe drop in white blood cells.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.